Documents
-
ANNUAL REPORT
20-F
-
DESCRIPTION OF SECURITIES
EX-2.1
-
BINDING LETTER OF INTENT, DATED JANUARY 20, 2026, BY AND BETWEEN YD BIO LIMITED AND SAFE SAVE MEDICAL CELL SCIENCES & TECHNOLOGY CO., LTD
EX-4.15
-
MASTER STRATEGIC ALLIANCE AGREEMENT, DATED FEBRUARY 24, 2026, BY AND BETWEEN YD BIO USA, INC. AND YC BIOTECH CO., LTD
EX-4.16
-
LIST OF SUBSIDIARIES
EX-8.1
-
CODE OF ETHICS
EX-11.1
-
INSIDER TRADING POLICY
EX-11.2
-
CERTIFICATION
EX-12.1
-
CERTIFICATION
EX-12.2
-
CERTIFICATION
EX-13.1
-
CERTIFICATION
EX-13.2
-
CONSENT OF MALONEBAILEY LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR YD BIO LIMITED
EX-15.1
-
CONSENT OF ARK PRO CPA & CO., INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
EX-15.2
-
LETTER OF MARCUM LLP, DATED APRIL 30, 2026
EX-16.1
-
LETTER OF ARK PRO CPA & CO., DATED APRIL 30, 2026
EX-16.3
-
COMPENSATION RECOVERY POLICY
EX-97.1
-
XBRL SCHEMA FILE
EX-101.SCH
-
XBRL CALCULATION FILE
EX-101.CAL
-
XBRL DEFINITION FILE
EX-101.DEF
-
XBRL LABEL FILE
EX-101.LAB
-
XBRL PRESENTATION FILE
EX-101.PRE
On sec.gov